



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,786	07/12/2001	Avi Ashkenazi	10466/84	3015
35489	35489 7590 04/28/2004		EXAMINER	
	HRMAN WHITE & MC	ANDRES,	ANDRES, JANET L	
275 MIDDLEFIELD ROAD MENLO PARK, CO 94025-3506			ART UNIT	PAPER NUMBER
	<b>,</b>		1646	
		DATE MAILED: 04/28/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application No.	Applicant(s)				
Office Action Summary		09/904,786	ASHKENAZI ET AL.				
		Examiner	Art Unit				
		Janet L. Andres	1646				
	The MAILING DATE of this communication ap	pears on the cover sheet with the c	orrespondence address				
THE I - Exter after - If the - If NO - Failu Any r earne	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reput of the provision of	136(a). In no event, however, may a reply be timply within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on <u>02 March 2004</u> .						
2a)⊠	This action is <b>FINAL</b> . 2b) ☐ Thi	s action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
5)□ 6)⊠ 7)□	<ul> <li>Claim(s) 39-43 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>Claim(s) is/are allowed.</li> <li>Claim(s) 39-43 is/are rejected.</li> <li>Claim(s) is/are objected to.</li> </ul>						
Applicati	ion Papers						
	The specification is objected to by the Examin						
10)	D) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
Attachmen	t(s)						
	, _ , _ , _ , _ , _ , _ , _ , _ , _ , _						
3) Inform	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 er No(s)/Mail Date		ate Patent Application (PTO-152)				

## RESPONSE TO AMENDMENT

1. Applicant's amendment filed 2 March 2004 is acknowledged. Claims 39-43 are pending and under examination in this office action. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior office action.

## Claim Rejections Maintained

2. The rejection of claims 39-43 under 35 U.S.C. 112, first paragraph, as lacking enablement is maintained for reasons of record in the office action of 20 November 2003.

Applicant argues that experimentation is not necessarily undue and that the art of immunotherapeutics as a whole is not unpredictable. Applicant argues that the MLR assay is widely used as a standard assay for immunomodulators. Applicant further argues that a "set pathway for experimentation" is provided and it would be routine to carry out *in vivo* experimentation to determine whether PRO335 or its antagonists are useful as immunomodulators.

Applicant's arguments have been fully considered but have not been found to be persuasive. While some experimentation need not be undue if there is an expectation of success, such an expectation is lacking for the instant invention. Activation of a mixed lymphocyte reaction is not widely used as an assay for immunotherapeutics. As was stated in the previous office action, it is widely used for determining histocompatibility, not for identifying immunostimulatory agents for therapeutic purposes or as targets. That a compound that stimulates this reaction might be of interest for further study does not serve to enable a use for it or antagonists of it. That it would be routine to carry out the experiments required to determine how it functions *in vivo* is not sufficient to predict that it could in fact be a therapeutic target.

Art Unit: 1646

Applicant has provided no guidance beyond a preliminary assay to suggest that the protein could be used as a therapeutic agent or that it could be a useful target for other agents. The ability of the artisan to undertake routine assays is not adequate guidance as to what those assays will indicate and thus as to whether the protein or antibodies to it could in fact be used as taught in the specification, but is merely an invitation to the artisan to use the current invention as a starting point for further experimentation. A "set pathway for experimentation" is not an invention, it is an idea for an invention, and the invitation to experiment to implement this invention, not the invention itself.

## NO CLAIM IS ALLOWED.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Andres whose telephone number is 571-272-0867. The examiner can normally be reached on Monday-Thursday and every other Friday, 8:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 571-272-0871. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Janet L. Andres, Ph.D. 20 April 2004

PATIENT EXAMINER